Your browser doesn't support javascript.
loading
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
Bryan E Jones; Patricia L Brown-Augsburger; Kizzmekia S Corbett; Kathryn Westendorf; Julian Davies; Thomas P Cujec; Christopher M Wiethoff; Jamie L Blackbourne; Beverly A Heinz; Denisa Foster; Richard E Higgs; Deepa Balasubramaniam; Lingshu Wang; Roza Bidshahri; Lucas Kraft; Yuri Hwang; Stefanie Zentelis; Kevin R Jepson; Rodrigo Goya; Maia A Smith; David W Collins; Samuel J Hinshaw; Sean A Tycho; Davide Pellacani; Ping Xiang; Krithika Muthuraman; Solmaz Sobhanifar; Marissa H Piper; Franz J Triana; Jorg Hendle; Anna Pustilnik; Andrew C Adams; Shawn J Berens; Ralph S Baric; David R Martinez; Robert W Cross; Thomas W Geisbert; Viktoriya Borisevich; Olubukola Abiona; Hayley M Belli; Maren de Vries; Adil Mohamed; Meike Dittmann; Marie Samanovic; Mark J Mulligan; Jory A Goldsmith; Ching-Lin Hsieh; Nicole V Johnson; Daniel Wrapp; Jason S McLellan; Bryan C Barnhart; Barney S Graham; John R Mascola; Carl L Hansen; Ester Falconer.
Affiliation
  • Bryan E Jones; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Patricia L Brown-Augsburger; Eli Lilly and Company, Indianapolis, IN, USA
  • Kizzmekia S Corbett; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  • Kathryn Westendorf; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Julian Davies; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Thomas P Cujec; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Christopher M Wiethoff; Eli Lilly and Company, Indianapolis, IN, USA
  • Jamie L Blackbourne; Eli Lilly and Company, Indianapolis, IN, USA
  • Beverly A Heinz; Eli Lilly and Company, Indianapolis, IN, USA
  • Denisa Foster; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Richard E Higgs; Eli Lilly and Company, Indianapolis, IN, USA
  • Deepa Balasubramaniam; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Lingshu Wang; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  • Roza Bidshahri; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Lucas Kraft; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Yuri Hwang; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Stefanie Zentelis; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Kevin R Jepson; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Rodrigo Goya; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Maia A Smith; AbCellera Biologics Inc., Vancouver, BC, Canada
  • David W Collins; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Samuel J Hinshaw; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Sean A Tycho; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Davide Pellacani; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Ping Xiang; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Krithika Muthuraman; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Solmaz Sobhanifar; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Marissa H Piper; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Franz J Triana; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Jorg Hendle; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Anna Pustilnik; Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
  • Andrew C Adams; Eli Lilly and Company, Indianapolis, IN, USA
  • Shawn J Berens; Eli Lilly and Company, Indianapolis, IN, USA
  • Ralph S Baric; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • David R Martinez; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Robert W Cross; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX; Department of Microbiology and Immunology, University of Texas Medical Branch,
  • Thomas W Geisbert; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX; Department of Microbiology and Immunology, University of Texas Medical Branch,
  • Viktoriya Borisevich; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX; Department of Microbiology and Immunology, University of Texas Medical Branch,
  • Olubukola Abiona; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  • Hayley M Belli; Department of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York, NY, USA
  • Maren de Vries; Department of Microbiology, New York University Grossman School of Medicine, New York, NY, USA
  • Adil Mohamed; Department of Microbiology, New York University Grossman School of Medicine, New York, NY, USA
  • Meike Dittmann; Department of Microbiology, New York University Grossman School of Medicine, New York, NY, USA
  • Marie Samanovic; NYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, N
  • Mark J Mulligan; NYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, N
  • Jory A Goldsmith; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
  • Ching-Lin Hsieh; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
  • Nicole V Johnson; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
  • Daniel Wrapp; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
  • Jason S McLellan; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
  • Bryan C Barnhart; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Barney S Graham; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  • John R Mascola; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  • Carl L Hansen; AbCellera Biologics Inc., Vancouver, BC, Canada
  • Ester Falconer; AbCellera Biologics Inc., Vancouver, BC, Canada
Preprint in English | bioRxiv | ID: ppbiorxiv-318972
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. One Sentence SummaryLY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.
License
cc_no
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2020 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2020 Document type: Preprint